Year |
Citation |
Score |
2023 |
Chang L, Jung NY, Atari A, Rodriguez DJ, Kesar D, Song TY, Rees MG, Ronan M, Li R, Ruiz P, Chaturantabut S, Ito T, van Tienen LM, Tseng YY, Roth JA, et al. Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nature Genetics. PMID 37749246 DOI: 10.1038/s41588-023-01515-7 |
0.404 |
|
2022 |
Joung J, Kirchgatterer PC, Singh A, Cho JH, Nety SP, Larson RC, Macrae RK, Deasy R, Tseng YY, Maus MV, Zhang F. CRISPR activation screen identifies BCL-2 proteins and B3GNT2 as drivers of cancer resistance to T cell-mediated cytotoxicity. Nature Communications. 13: 1606. PMID 35338135 DOI: 10.1038/s41467-022-29205-8 |
0.319 |
|
2022 |
Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. The Prostate. PMID 35084050 DOI: 10.1002/pros.24305 |
0.313 |
|
2020 |
Tseng Y, Keskula P, Deasy R, Hong A, Chatterji P, Vazquez F, Bass A, Hare BV, Sandak D, Ligon K, Boehm J. Abstract PR09: A systematic approach to create patient-derived models of rare tumors Cancer Research. 80. DOI: 10.1158/1538-7445.Camodels2020-Pr09 |
0.504 |
|
2019 |
Chan EM, Shibue T, McFarland JM, Gaeta B, Ghandi M, Dumont N, Gonzalez A, McPartlan JS, Li T, Zhang Y, Bin Liu J, Lazaro JB, Gu P, Piett CG, Apffel A, ... ... Tseng YY, et al. WRN helicase is a synthetic lethal target in microsatellite unstable cancers. Nature. PMID 30971823 DOI: 10.1038/S41586-019-1102-X |
0.455 |
|
2019 |
Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, et al. A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nature Communications. 10: 1617. PMID 30962421 DOI: 10.1038/S41467-019-09277-9 |
0.399 |
|
2019 |
Tseng YY, Boehm JS. From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Current Opinion in Genetics & Development. 54: 33-40. PMID 30928774 DOI: 10.1016/J.Gde.2019.02.007 |
0.5 |
|
2019 |
Hong AL, Tseng YY, Wala JA, Kim WJ, Kynnap BD, Doshi MB, Kugener G, Sandoval GJ, Howard TP, Li J, Yang X, Tillgren M, Ghandi M, Sayeed A, Deasy R, et al. Renal medullary carcinomas depend upon loss and are sensitive to proteasome inhibition. Elife. 8. PMID 30860482 DOI: 10.7554/Elife.44161 |
0.408 |
|
2019 |
Tseng YY, Bagchi A. Engineering Large Genomic Rearrangement in Mouse Embryonic Stem Cell for Cancer Gene Discovery. Methods in Molecular Biology (Clifton, N.J.). 1907: 197-212. PMID 30543002 DOI: 10.1007/978-1-4939-8967-6_16 |
0.741 |
|
2018 |
Guenther LM, Dharia NV, Ross L, Saur Conway A, Robichaud AL, Catlett JL, Wechsler C, Frank ES, Goodale AB, Church AJ, Tseng YY, Guha R, McKnight C, Janeway KA, Boehm JS, et al. A combination CDK4/6 and IGF1R inhibitor strategy for Ewing sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30397176 DOI: 10.1158/1078-0432.Ccr-18-0372 |
0.395 |
|
2018 |
Hong AL, Tseng Y, Kynnap BD, Doshi MB, Wala J, Sandoval G, Church AJ, Mullen E, Kadoch C, Roberts CWM, Beroukhim R, Boehm JS, Hahn WC. Abstract B18: Modeling renal medullary carcinomas identifies druggable vulnerabilities in SMARCB1-deficient cancers Cancer Research. 78. DOI: 10.1158/1538-7445.Pedca17-B18 |
0.524 |
|
2018 |
Ben-David U, Ha G, Tseng Y, Greenwald NF, Oh C, Shih J, McFarland JM, Wong B, Boehm JS, Beroukhim R, Golub TR. Abstract 1028: Patient-derived xenografts undergo mouse-specific tumor evolution Tumor Biology. DOI: 10.1158/1538-7445.Am2018-1028 |
0.342 |
|
2018 |
De Smet F, Tseng Y, Ramkissoon S, Ramkissoon L, Pelton K, Luna RF, Panovska D, Schoolcraft K, Watkinson F, Bilton S, Hung V, Chow K, Geduldig J, Becker S, Jones R, et al. TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS Neuro-Oncology. 20: vi271-vi271. DOI: 10.1093/Neuonc/Noy148.1126 |
0.496 |
|
2017 |
Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, McFarland JM, Wong B, Boehm JS, Beroukhim R, Golub TR. Patient-derived xenografts undergo mouse-specific tumor evolution. Nature Genetics. PMID 28991255 DOI: 10.1038/Ng.3967 |
0.503 |
|
2017 |
Joung J, Engreitz JM, Konermann S, Abudayyeh OO, Verdine VK, Aguet F, Gootenberg JS, Sanjana NE, Wright JB, Fulco CP, Tseng YY, Yoon CH, Boehm JS, Lander ES, Zhang F. Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature. PMID 28792927 DOI: 10.1038/Nature23451 |
0.415 |
|
2017 |
Hong AL, Tseng Y, Kynnap BD, Doshi MB, Sandoval G, Oh C, Sayeed A, Shubhroz G, Church AJ, Keskula P, Peng A, Clemons PA, Tsherniak A, Vazquez F, Rodriguez-Galindo C, et al. Abstract B17: Identification of Druggable Targets through Functional Multi-Omics in Renal Medullary Carcinoma Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B17 |
0.464 |
|
2017 |
Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Alkhairy S, Oh C, Peng A, Deasy R, Sayeed A, Ronning P, et al. Abstract 1953: Accelerating prediction of pediatric and rare cancer vulnerabilities using next-generation cancer models Cancer Research. 77: 1953-1953. DOI: 10.1158/1538-7445.Am2017-1953 |
0.5 |
|
2017 |
Tashiro K, Tseng Y, Konety B, Bagchi A. MP99-18 ROLE OF LONG NON-CODING RNA PVT1 IN REGULATING MYC IN HUMAN CANCER Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.3104 |
0.717 |
|
2016 |
Giannikou K, Malinowska IA, Pugh TJ, Yan R, Tseng YY, Oh C, Kim J, Tyburczy ME, Chekaluk Y, Liu Y, Alesi N, Finlay GA, Wu CL, Signoretti S, Meyerson M, et al. Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. Plos Genetics. 12: e1006242. PMID 27494029 DOI: 10.1371/Journal.Pgen.1006242 |
0.361 |
|
2016 |
Hong AL, Tseng YY, Cowley GS, Jonas O, Cheah JH, Kynnap BD, Doshi MB, Oh C, Meyer SC, Church AJ, Gill S, Bielski CM, Keskula P, Imamovic A, Howell S, et al. Integrated genetic and pharmacologic interrogation of rare cancers. Nature Communications. 7: 11987. PMID 27329820 DOI: 10.1038/Ncomms11987 |
0.507 |
|
2016 |
Sarver AL, Murray CD, Temiz NA, Tseng YY, Bagchi A. MYC and PVT1 synergize to regulate RSPO1 levels in breast cancer. Cell Cycle (Georgetown, Tex.). 0. PMID 26889781 DOI: 10.1080/15384101.2016.1149660 |
0.759 |
|
2016 |
Hong AL, Tseng Y, Cowley G, Jonas O, Cheah J, Doshi M, Kynnap B, Oy C, Keskula P, Kryukov G, Cima M, Langer R, Schreiber S, Root D, Boehm J, et al. Abstract PR04: Integration of CRISPR-Cas9, RNAi and pharmacologic screens identify actionable targets in a rare cancer Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-Pr04 |
0.445 |
|
2016 |
Tseng Y, Keskula P, Hong AL, Gill S, Cheah JH, Kryukov GV, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, et al. Abstract B26: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-B26 |
0.539 |
|
2016 |
Hong AL, Cowley GS, Tseng Y, Cheah JH, Jonas O, Doshi MB, Kynnap BD, Oh C, Meyer S, Clemons P, Burger M, Vazquez F, Weir B, Kryukov GV, Church A, et al. Abstract B38: Developing a functional genomics platform to interrogate rare pediatric cancers Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B38 |
0.488 |
|
2016 |
Tseng Y, Hong A, Keskula P, Gill S, Cheah J, Kryukov G, Tsherniak A, Vazquez F, Cowley G, Oh C, Peng A, Sayeed A, Deasy R, Ronning P, Kantoff P, et al. Abstract 4367: Accelerating prediction of tumor vulnerabilities using next-generation cancer models Cancer Research. 76: 4367-4367. DOI: 10.1158/1538-7445.Am2016-4367 |
0.549 |
|
2016 |
Tashiro K, Klink R, Zetterval J, Diedrich V, Tseng Y, Bagchi A. Abstract 2663: Insights into the oncogenic basis of long non-coding RNA PVT1 in human cancer Cancer Research. 76: 2663-2663. DOI: 10.1158/1538-7445.Am2016-2663 |
0.798 |
|
2015 |
Tseng YY, Bagchi A. The PVT1-MYC duet in cancer. Molecular & Cellular Oncology. 2: e974467. PMID 27308428 DOI: 10.4161/23723556.2014.974467 |
0.763 |
|
2015 |
Tseng Y, Bagchi A. Abstract PR01: Long noncoding RNA PVT1 potentiates MYC in human cancers with 8q24 gain Molecular Cancer Research. 13. DOI: 10.1158/1557-3125.Myc15-Pr01 |
0.794 |
|
2015 |
Berger AH, Kim E, Brooks A, Ilic N, Shrestha Y, Tseng Y, Wu X, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Kantoff P, et al. Abstract PR07: Towards precision functional genomics via next-generation functional mapping of cancer variants Cancer Research. 75: 957-957. DOI: 10.1158/1538-7445.Transcagen-Pr07 |
0.546 |
|
2015 |
Berger A, Kim E, Brooks A, Shrestha Y, Tseng Y, Wu X, Ilic N, Zou L, Kamburov A, Yang X, Zhu C, Keskula P, Seepo S, Hong A, Doench J, et al. Abstract 957: Towards precision functional genomics via next-generation functional mapping of cancer variants Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2015-957 |
0.382 |
|
2014 |
Tseng YY, Moriarity BS, Gong W, Akiyama R, Tiwari A, Kawakami H, Ronning P, Reuland B, Guenther K, Beadnell TC, Essig J, Otto GM, O'Sullivan MG, Largaespada DA, Schwertfeger KL, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 512: 82-6. PMID 25043044 DOI: 10.1038/Nature13311 |
0.771 |
|
2012 |
Tseng Y, Beadnell T, Schwertfeger K, Bagchi A. Abstract 3288: A chromosome engineering mouse model to identify mechanisms by which duplication of 8q24 promotes human breast cancer Cancer Research. 72: 3288-3288. DOI: 10.1158/1538-7445.Am2012-3288 |
0.733 |
|
2010 |
Tseng Y, Schwertfeger KL, Bagchi A. Abstract 3272: Chromosome engineered mouse model for human 8q24 amplicon observed in breast cancer patients Cancer Research. 70: 3272-3272. DOI: 10.1158/1538-7445.Am10-3272 |
0.76 |
|
Low-probability matches (unlikely to be authored by this person) |
2010 |
Wang HH, Yeh HI, Wang CY, Su CH, Wu YJ, Tseng YY, Lin YC, Tsai CH. C-reactive protein, sodium azide, and endothelial connexin43 gap junctions. Cell Biology and Toxicology. 26: 153-63. PMID 19415183 DOI: 10.1007/S10565-009-9125-Y |
0.277 |
|
2024 |
Mittal K, Cooper GW, Lee BP, Su Y, Skinner KT, Shim J, Jonus HC, Kim WJ, Doshi M, Almanza D, Kynnap BD, Christie AL, Yang X, Cowley GS, Leeper BA, ... ... Tseng YY, et al. Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin. Communications Biology. 7: 426. PMID 38589567 DOI: 10.1038/s42003-024-06140-6 |
0.263 |
|
2024 |
Ho CC, Gilbert MB, Urtecho G, Lee H, Drew DA, Klempner SJ, Cho JS, Ryan TJ, Rustgi N, Lee H, Lee J, Caraballo A, Magicheva-Gupta MV, Rios C, Shin AE, ... Tseng YY, et al. Stool protein mass spectrometry identifies biomarkers for the early detection of diffuse-type gastric cancer. Cancer Prevention Research (Philadelphia, Pa.). PMID 38669694 DOI: 10.1158/1940-6207.CAPR-23-0449 |
0.256 |
|
2017 |
Viswanathan VS, Ryan MJ, Dhruv HD, Gill S, Eichhoff OM, Seashore-Ludlow B, Kaffenberger SD, Eaton JK, Shimada K, Aguirre AJ, Viswanathan SR, Chattopadhyay S, Tamayo P, Yang WS, Rees MG, ... ... Tseng YY, et al. Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature. PMID 28678785 DOI: 10.1038/Nature23007 |
0.251 |
|
2007 |
Tseng YY, Yu CW, Liao VH. Caenorhabditis elegans expresses a functional ArsA. The Febs Journal. 274: 2566-72. PMID 17419726 DOI: 10.1111/J.1742-4658.2007.05791.X |
0.251 |
|
2018 |
Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL, Ju J, Liu IH, Chiou SH, Salahudeen AA, Smith AR, Deutsch BC, Liao L, Zemek AJ, Zhao F, Karlsson K, ... ... Tseng YY, et al. Organoid Modeling of the Tumor Immune Microenvironment. Cell. 175: 1972-1988.e16. PMID 30550791 DOI: 10.1016/J.Cell.2018.11.021 |
0.237 |
|
2007 |
Wang H, Kung C, Tseng Y, Lin Y, Chen C, Tsai C, Yeh H. S30-6 ACTIVATION OF ENDOTHELIAL CELLS TO PATHOLOGICAL STATUS BY DOWN-REGULATION OF CONNEXIN43 International Journal of Cardiology. 122: S50. DOI: 10.1016/S0167-5273(08)70485-6 |
0.226 |
|
2008 |
Wang HH, Kung CI, Tseng YY, Lin YC, Chen CH, Tsai CH, Yeh HI. Activation of endothelial cells to pathological status by down-regulation of connexin43. Cardiovascular Research. 79: 509-18. PMID 18445604 DOI: 10.1093/Cvr/Cvn112 |
0.223 |
|
2019 |
Hong AL, Tseng Y, Wala JA, Kim W, Kynnap BD, Doshi MB, Kugener G, Sandoval GJ, Howard TP, Li J, Yang X, Tillgren M, Ghandi M, Sayeed A, Deasy R, et al. Author response: Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition Elife. DOI: 10.7554/Elife.44161.051 |
0.212 |
|
2006 |
Liao VH, Chien MT, Tseng YY, Ou KL. Assessment of heavy metal bioavailability in contaminated sediments and soils using green fluorescent protein-based bacterial biosensors. Environmental Pollution (Barking, Essex : 1987). 142: 17-23. PMID 16298031 DOI: 10.1016/J.Envpol.2005.09.021 |
0.194 |
|
2017 |
Joung J, Engreitz JM, Konermann S, Abudayyeh OO, Verdine VK, Aguet F, Gootenberg JS, Sanjana NE, Wright JB, Fulco CP, Tseng YY, Yoon CH, Boehm JS, Lander ES, Zhang F. Erratum: Genome-scale activation screen identifies a lncRNA locus regulating a gene neighbourhood. Nature. 549: 418. PMID 28933431 DOI: 10.1038/nature24009 |
0.181 |
|
2023 |
McCue C, Atari A, Parks S, Tseng YY, Varanasi KK. Reducing Cancer Cell Adhesion using Microtextured Surfaces. Small (Weinheim An Der Bergstrasse, Germany). e2302401. PMID 37559167 DOI: 10.1002/smll.202302401 |
0.158 |
|
2024 |
Chang L, Jung NY, Atari A, Rodriguez DJ, Kesar D, Song TY, Rees MG, Ronan M, Li R, Ruiz P, Chaturantabut S, Ito T, van Tienen LM, Tseng YY, Roth JA, et al. Author Correction: Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. Nature Genetics. PMID 38396071 DOI: 10.1038/s41588-024-01680-3 |
0.072 |
|
Hide low-probability matches. |